Jens Hillengass, MD, PhD

Clinical Scenario: Implementation of Bispecific Therapy for Relapsed Refractory Multiple Myeloma in a Community Center

Ajai Chari, MD;Thomas G. Martin, MD;Jens Hillengass, MD, PhD ;Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ;Louis Williams, MD;Shebli Atrash, MD ;Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez Valdes, MD ;Shambavi Richard, MD

November 27th 2024

Panelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.

Clinical Scenario: A 58-Year Old Woman with Relapsed Refractory Mutiple Myeloma, post-ASCT, MRD-negative, on Bispecific Therapy

Ajai Chari, MD;Thomas G. Martin, MD;Jens Hillengass, MD, PhD ;Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ;Louis Williams, MD;Shebli Atrash, MD ;Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez Valdes, MD ;Shambavi Richard, MD

November 20th 2024

Panelists discuss how to approach treatment decisions and management strategies for a 58-year-old woman with relapsed/refractory multiple myeloma who is post-autologous stem cell transplant, MRD-negative, and currently receiving bispecific antibody therapy, considering factors such as prior treatments, response duration, and long-term treatment goals.

Dosing Interval and Considerations for Bispecifics Combination in Relapsed Refractory Multiple Myeloma

Ajai Chari, MD;Thomas G. Martin, MD;Jens Hillengass, MD, PhD ;Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ;Louis Williams, MD;Shebli Atrash, MD ;Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez Valdes, MD ;Shambavi Richard, MD

November 20th 2024

Panelists discuss how optimizing dosing intervals and carefully considering combination strategies for bispecific antibodies in relapsed/refractory multiple myeloma could enhance treatment efficacy while managing toxicities and improving patient quality of life.

Sequencing Therapies in Relapsed Refractory Multiple Myeloma: Bispecifics and CAR T-Cell Therapies

Ajai Chari, MD;Thomas G. Martin, MD;Jens Hillengass, MD, PhD ;Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ;Louis Williams, MD;Shebli Atrash, MD ;Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez Valdes, MD ;Shambavi Richard, MD

November 13th 2024

Panelists discuss how the optimal sequencing of bispecific antibodies and CAR T-cell therapies in relapsed/refractory multiple myeloma could maximize treatment efficacy and improve patient outcomes in this challenging disease setting.

OPTec: Outpatient Step Up Administration of Teclistamab: Implications in Real-World Practice

Ajai Chari, MD;Thomas G. Martin, MD;Jens Hillengass, MD, PhD ;Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ;Louis Williams, MD;Shebli Atrash, MD ;Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez Valdes, MD ;Shambavi Richard, MD

November 13th 2024

Panelists discuss how the OPTec study, which explores outpatient step-up administration of teclistamab, could impact real-world practice by potentially improving patient convenience and reducing healthcare resource utilization in the treatment of multiple myeloma.

Prophylactic Tocilizumab in MajesTEC-1 for the Reduction of CRS

Ajai Chari, MD;Thomas G. Martin, MD;Jens Hillengass, MD, PhD ;Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ;Louis Williams, MD;Shebli Atrash, MD ;Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez Valdes, MD ;Shambavi Richard, MD

November 6th 2024

Panelists discuss how prophylactic use of tocilizumab in the MajesTEC-1 trial may reduce the incidence and severity of cytokine release syndrome (CRS) in patients receiving bispecific antibody therapy for multiple myeloma, potentially improving treatment safety and tolerability.

Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: RedirecTT-1 Follow-Up

Ajai Chari, MD;Thomas G. Martin, MD;Jens Hillengass, MD, PhD ;Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ;Louis Williams, MD;Shebli Atrash, MD ;Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez Valdes, MD ;Shambavi Richard, MD

November 6th 2024

Panelists discuss how the follow-up results from the RedirecTT-1 study provide insights into the long-term efficacy and safety of bispecific antibody combinations in treating relapsed/refractory multiple myeloma, potentially shaping future treatment approaches for this challenging disease.

Bispecific Antibody Combinations In Relapsed Refractory Multiple Myeloma: TRIMM-2 Study

Ajai Chari, MD;Thomas G. Martin, MD;Jens Hillengass, MD, PhD ;Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ;Louis Williams, MD;Shebli Atrash, MD ;Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez Valdes, MD ;Shambavi Richard, MD

October 30th 2024

Panelists discuss how the TRIMM-2 study explores the potential of combining bispecific antibodies to enhance treatment efficacy in patients with relapsed/refractory multiple myeloma, potentially offering a novel therapeutic strategy for this difficult-to-treat condition.

Talquetamab, a GPRC5DxCD3 bispecific antibody (BsAb), for Relapsed Refractory Multiple Myeloma: MonumenTAL-1 Data and Implications

Ajai Chari, MD;Thomas G. Martin, MD;Jens Hillengass, MD, PhD ;Beth Faiman PhD, MSN, APN-BC,BMTCN, AOCN, FAAN, FAPO ;Louis Williams, MD;Shebli Atrash, MD ;Donna Catamero, ANP-BC, OCN, CCRC;Cesar Rodriguez Valdes, MD ;Shambavi Richard, MD

October 30th 2024

Panelists discuss how Talquetamab, a novel GPRC5DxCD3 bispecific antibody, shows promising results in treating relapsed/refractory multiple myeloma based on the MonumenTAL-1 trial data, potentially offering a new therapeutic option for this challenging patient population.

Jens Hillengass, MD, PhD

Articles

Latest Updated Articles